Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Adaptive Biotechnologies Corporation before investing.

In this article, we go over a few key elements for understanding Adaptive Biotechnologies Corporation’s stock price such as:

• Adaptive Biotechnologies Corporation’s current stock price and volume
• Why Adaptive Biotechnologies Corporation’s stock price changed recently
• Upgrades and downgrades for ADPT from analysts
• ADPT’s stock price momentum as measured by its relative strength

About Adaptive Biotechnologies Corporation (ADPT)

Before we jump into Adaptive Biotechnologies Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Want to learn more about Adaptive Biotechnologies Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Adaptive Biotechnologies Corporation.

Adaptive Biotechnologies Corporation’s Stock Price as of Market Close

As of January 16, 2026, 4:00 PM, CST, Adaptive Biotechnologies Corporation’s stock price was $17.520.

Adaptive Biotechnologies Corporation is down 1.46% from its previous closing price of $17.780.

During the last market session, Adaptive Biotechnologies Corporation’s stock traded between $17.400 and $17.890. Currently, there are approximately 152.43 million shares outstanding for Adaptive Biotechnologies Corporation.

Adaptive Biotechnologies Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Adaptive Biotechnologies Corporation Stock Price History

Adaptive Biotechnologies Corporation’s (ADPT) price is currently up 7.88% so far this month.

During the month of January, Adaptive Biotechnologies Corporation’s stock price has reached a high of $18.500 and a low of $15.310.

Over the last year, Adaptive Biotechnologies Corporation has hit prices as high as $20.760 and as low as $6.255. Year to date, Adaptive Biotechnologies Corporation’s stock is up 7.88%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Adaptive Biotechnologies Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 16, 2026, there were 0 analysts who downgraded Adaptive Biotechnologies Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Adaptive Biotechnologies Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Adaptive Biotechnologies Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Adaptive Biotechnologies Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Adaptive Biotechnologies Corporation (ADPT) by visiting AAII Stock Evaluator.

Relative Price Strength of Adaptive Biotechnologies Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 16, 2026, Adaptive Biotechnologies Corporation has a weighted four-quarter relative price strength of 18.61%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Adaptive Biotechnologies Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Adaptive Biotechnologies Corporation Stock Price: Bottom Line

As of January 16, 2026, Adaptive Biotechnologies Corporation’s stock price is $17.520, which is down 1.46% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Adaptive Biotechnologies Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.